Monday Jul 21
Synageva BioPharma Corp Given Consensus Rating of "Buy" by Analysts
Synageva BioPharma Corp has been given an average recommendation of "Buy" by the ten ratings firms that are currently covering the stock, AnalystRatingsNetwork.com reports .
GlycoMimetics Appoints Mark A. Goldberg, M.D. to Board of Directors
GAITHERSBURG, Md. -- -- GlycoMimetics, Inc. announced today the addition of Mark A. Goldberg, M.D. to its Board of Directors.
Synageva Biopharma Corp. Files SEC Form 4, Statement of Changes in...
There was one document filed with this form. The 02421, 357-9900. Our editors provided additional information about Form 4: Every director, officer or owner of more than ten percent of a class of equity securities registered under Section 12 of the '34 Act must file with the Commission a statement of ownership regarding such security.
Applied Clinical Trials
Synageva BioPharma? Reports Positive Top-Line Results From Phase 3...
Phase 3 Study Meets Primary Endpoint and Six Secondary Endpoints Across Multiple Disease-Related Abnormalities Conference Call and Webcast to be Held Today at 4:30 p.m. EDT /PRNewswire/ -- Synageva BioPharma Corp. , a biopharmaceutical company developing therapeutic products for rare diseases, announced today that the global, randomized, ... (more)
Synageva BioPharma(TM) Reports Positive Top-Line Results From Phase 3 ...
Synageva BioPharma Corp. , a biopharmaceutical company developing therapeutic products for rare diseases, announced today that the global, randomized, double-blind, placebo-controlled Phase 3 ARISE trial of sebelipase alfa in 66 children and adults with lysosomal acid lipase deficiency met the primary endpoint of normalization of alanine ... (more)